GelCel is a cell culture system that can mimic the micro-scale physiological conditions of the body. It was designated as NOVEL in the Signature Square program.
BOSTON, MA (PRWEB) January 31, 2016
The One Million Solutions in Health™ Technology Evaluation Consortium™ designated GelCel as Novel technology via the Signature Square™ program. This novel technology from the University of Pennsylvania is a cell culture system that can mimic the micro-scale physiological conditions of the body.
Dr. Kaori Ihida-Stansbury, Research Associate Professor, was the presenter. She is the Principal Investigator and person responsible for developing this technology which received the designation of GelCel as Novel.
GelCel is a cell culture system that can mimic the micro-scale physiological conditions of the body. Scientists work with model systems that are meant to be small-scale versions of the real life conditions in the body. However, many of the scientists work on micro-level models with cells using plastic-based culture containers, which are far from a person’s actual body environment.
Because these plastic culture containers are very much stiffer than the physiological condition of the body, the results gained while using them cannot be easily translated to the human body. To solve this problem, the team developed a cell culture system with tunable substrate that allows scientists to replicate the mechanics of physiological, normal or pathologic conditions.
“The Technology Evaluation Consortium is pleased to be evaluating new technology from the University of Pennsylvania,” stated Dawn Van Dam, President and CEO of One Million Solutions in Health. “The goal of the Consortium is to bring together experts from around the world to expedite the development of scientific technology – we are pleased for GelCel to be part of this process.”
The Signature Square program provides feedback to technology or service providers (commercial, academic, government, healthcare institutions, etc.) based on confidential reviews by Subject Matter Experts in the life sciences and health care sectors for new or established solutions. The evaluation occurs on two dimensions: 1) Value Proposition to the Marketplace and 2) Market or Partner Readiness.
A One Million Solutions in Health Signature Square evaluation uses a combination of quantitative research, numerical scoring and respondents’ comments, or qualitative feedback, as it reflects the offering’s differentiated position in the market. By focusing on end-user feedback, and applying a graphical treatment and a uniform set of evaluation criteria, a Signature Square helps research teams quickly ascertain how well a technology or service is positioned to provide value to the market and how ready it is to provide that value.
The Signature Square is an opportunity for technology or service providers to receive direct evaluations and feedback which can then be used to inform potential investors, end users and/or partners. It can also be utilized as a component towards understanding the technology or service and its potential to contribute to health care.
The Subject Matter Experts are members of the Technology Evaluation Consortium with specific expertise in the relevant area for each technology, including individuals from top biopharmaceutical, diagnostic, device, health data or healthcare organizations in the field, as relevant. One Million Solutions in Health aims to have a broad representation of feedback and advice from relevant Subject Matter Experts in each area. These experts evaluate the technology or service such that the feedback received is valid and valuable.
The positioning within the Signature Square is related to the aforementioned criteria, along with the point-in-time at which it has been evaluated. Consequently, a technology evaluated early could be considered an Innovator, but by addressing the feedback received in the process, could eventually be considered a Blockbuster.
For an opportunity to join the Technology Evaluation Consortium, and review the detailed information, video and evaluation for this technology: GelCel as Novel, please contact Dawn Van Dam at One Million Solutions in Health (dawn.vandam(at)onemillionsolutionsinhealth(dot)org).
ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.
In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.
As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!
ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM
The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.
The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.
GelCel is a start-up company from the University of Pennsylvania. On the team are two cell biologists (Dr. Kaori Ihida-Stansbury, PhD; and a bioengineer, Mithil Chokshi, MSE). Kaori’s background is in cardiovascular systems with specific focus on the micro-environmental guidance in progenitor cell development by manipulating synthetic substrates; and Mithil’s background is in polymer chemistry, drug discovery, and systems biology. He has also been working as an intern at the Penn Center for Innovation (PCI; former CTT of the University of Pennsylvania) to research and evaluate patent applications for on-campus technologies with knowledge of commercialization, marketing, and business development. Therefore, we have a balanced mix of technology, business and science backgrounds and are eager to have opportunities to cultivate and develop the GelCel product.
Dawn Van Dam
President and CEO